Our findings revealed that both PD-1 and PDL-1 are poor prognostic factors for HCC patient survival, with insights about the composition of the TME (cold vs. hot tumors), ongoing clinical trials for HCC immunotherapy utilizing PD-1/PDL-1 inhibitors, and possible combination therapies. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.